Posted: April 1, 2017 at 8:43 am
Metformin in breast cancer Nature.com A new study published in the Journal of Clinical Oncology reports that metformin improves the prognosis of patients with HER2-positive, hormone receptor (HR)-positive breast cancer and diabetes mellitus. The phase III randomized ALTTO trial included ... |
See the rest here:
Metformin in breast cancer - Nature.com
Posted: April 1, 2017 at 8:43 am
When a 92-year-old woman with dementia in my companys managed long term care (MLTC) plan had to switch from oral diabetes medication to insulin recently, Yael Reich, a nurse diabetes specialist with the Visiting Nurse Service of New York (VNSNY), was the person who arranged for a friend to administer the shots. In her dual role as diabetes educator and complex case manager, Yael advises VNSNY nurses across New York City, Westchester and Nassau on how to help our patients and health plan members with diabetes manage their glucose levels. Approximately one-third of our patients have diabetes in addition to their primary diagnosis, says Yael, whos worked with VNSNY for 23 years and has been a diabetes specialist and educator since 2004. This means our nurses are treating thousands of patients with diabetes on any given day.
Type 2 diabetes, in which a persons blood glucose levels become chronically elevated, can lead to kidney and eye damage, cardiovascular disease and other health problems. In addition to reviewing with our nurses and their patients the proper way to administer diabetes medications that keep blood glucose levels under control, Yael will also explain to them how weight loss, a healthy diet, exercise, and other lifestyle changes can help prevent diabetes in those who are at risk of developing it, and minimize the need for medication in those who already have diabetes.
According to the CDC, more than 29 million Americans are living with diabetes, and 86 million are living with prediabetes, a serious health condition that increases a persons risk of type 2 diabetes and other chronic diseases. With type 2 diabetes rates in the U.S. continuing to riseone in eleven Americans now has the disease, according to the most recent estimates, including one out of four people aged 65 or olderunderstanding how to prevent and control the condition through lifestyle changes and proper medical care is more important than ever. And since people who have diabetes or are at high risk of developing the condition make up a disproportionate share of home care patients and clients, the visiting nurses and nurse educators employed by home care agencies like VNSNY play a lead role in helping to keep this dangerous condition in check.
Bridging the Gap Between Medical Advice and How People Really Live
One important way that frontline home care clinicians make a difference is by helping their patients bridge the gap between advice they receive from medical professionals and taking steps to follow this advice on a daily basis in the real world. For example, when registered nurse Sheniqua Johnson was providing care recently for a patient with elevated blood glucose levels, her patient agreed readily with her advice to avoid foods high in sugar and processed carbohydratesbut then consistently refused to act on her recommendations. He didnt want someone coming in from the outside telling him what to do, Sheniqua says. On speaking with him further during her home visits, she learned that he was originally from West Africa, and with that information in hand, she was able to engage him around healthy foods hed grown up with and steer him toward a healthier diet.
By visiting with people in their homes, our nurses and nurse educators also come to understand real-life barriers that may not be as obvious to other medical professionals. Fresh vegetables and fruit are often difficult to access in lower income neighborhoods, and can be costly when they are available. As a result, people frequently turn to more convenient and affordablebut less healthyalternatives. Nurse Johnson recalls caring for a woman who was struggling with diabetes, and noticing that her kitchen shelves were crowded with boxes of sugar-sweetened cereal. To save money, thats what I eat for dinner, the woman told her, explaining that she thought she was following her doctors instructions. Johnson was able to help her patient identify easy-to-prepare alternative foods, such as frozen vegetables and lentils, in her local grocery store, that she could buy for the same price to provide better nutrition and help keep blood glucose levels in check.
Our frontline clinicians can also help people who havent developed diabetes identify and correct their risk factors, by walking them through diabetes risk assessments such as the one the American Diabetes Association (ADA) offers onlinea test which you can take yourself by accessing it here. When an assessment indicates that someones risk of developing type 2 diabetes is high, our clinicians will then arrange for them to have their blood glucose levels tested to determine whether they have diabetes or prediabetes (an early warning sign that blood glucose levels arent being adequately controlled).
Encouraging Daily Diabetes-Fighting Behavior
Whether someone has diabetes, prediabetes, or is simply at risk of getting the disease, our nurses and diabetes educators regularly encourage them to take evidence-based steps to prevent diabetes from developing, or manage their condition more effectivelyincluding losing weight, engaging in physical activity each day, and eating healthier foods. Many of our home health aides are now also trained as Health Coaches, and are using proven techniques such as motivational interviewing to help patients make and maintain important lifestyle changes that help them better manage their diabetes and other chronic medical conditions.
In addition to frontline nurses, diabetes educators and home health aides at home care agencies, community-based clinicians also play a significant role in combating the diabetes epidemic. Primary care physicians now routinely refer patients to diabetes educators for practical advice on how to make changes in their daily diets and safely increase physical activity. This is one more confirmation that when it comes to defeating type 2 diabetes, the solution begins at home.
Start your workday the right way with the news that matters most.
See the original post here:
Frontline Homecare Professionals Make a Difference in Keeping Diabetes In Check - Huffington Post
Posted: March 31, 2017 at 3:48 am
Biotechnology is a top-notch field of study that emerged into the scientific world as a result of revolutions in Biology, Chemistry, Informatics, and Engineering. It is considered to be an applied branch of Biology. Biotechnology helps out this old and respectable field of science keep up with the pace of time and remain competitive in the contemporary world.
With a Master in Biotechnology, students will study the use of living organisms and bioprocesses in technology, engineering, medicine, agriculture and results in all kinds of bioproducts, from genetically modified food to serious cutting-edge devices used to carry out gene therapy. Students in Master in Biotechnology programs may also explore bioinformatics, which is the application of statistics and computer science to the field of molecular biology. Bioinformatics is extremely important for contemporary biological and molecular researches because the data amount there grows by geometric progression and it is necessary to have adequate technology to process it. Bioinformatic methods are widely used for mapping and analyzing DNA and protein samples, as well as for the study of genetics and molecular modeling. Biotechnology and Bioinformatics do a great favour to traditional fields of study, refreshing them with new methods of research, which allows their drastic development, and you can make your contribution with a Master in Biotechnology degree.
Find out about various Master in Biotechnology programs by following the links below. Don't hesitate to send the "Request free information" form to come in contact with the relevant person at the school and get even more information about the specific Master in Biotechnology program you are interested in.
Visit link:
Best Master's Degrees in Biotechnology 2017
Posted: March 31, 2017 at 3:48 am
Technology and biotechnology stocks once again top our list of momentum charts to watch.
Achaogen Inc. AKAO, -2.26% had an important snapback session on Tuesday, gaining $2.12, or 9.7%, to $23.90 on over 2 million shares traded. The move came on news that venture capitalist Robert Duggan disclosed a 5.7% stake in the late-stage biopharmaceutical company. Volume was the strongest on an up-day all year, and the stock has now bounced off rising trendline support after a 10-day pullback from the top of the channel to the bottom. If the stock can get through resistance, which is now up around Tuesdays high at $24.46, it could challenge recent highs around $26.75-$27.75 on the way to the top of the channel at over $30.
Cara Therapeutics Inc. CARA, -7.36% had a nice follow-through on Tuesday, jumping 94 cents, or 5%, to $19.09, on 7.6 million shares traded. The biotech company reported positive results in a trial of a treatment for uremic pruritus, or UP. The stock reached $20.24 intraday, the highest its been since September 2015. It came down in the afternoon and didnt close great, but from the standpoint of the daily pattern as well technicals and volume, the stock looks strong. It has climbed nicely off rising trendline support toward mid-channel in the past two weeks. The stock needs to hold lateral support at around $17.50. A move through Tuesdays high could lead to $23 short-term and $27 intermediate-term.
Kopin Corp. KOPN, -0.24% maker of wearable technologies and display products, had nice action on Tuesday, especially in the afternoon when it ran from about $3.90 to $4.19, backing off a little at the close. Net on the day, it gained 8 cents, or 2%, to $4.11 on strong volume of 643,000 shares. Volume has been strong in general in the past few weeks, indicating possible accumulation, and Tuesday saw the stock edge above its breakout point at around $4.09. Watch for $4.75 and then $5-$5.25 as targets.
Nektar Therapeutics NKTR, -3.93% had a breakout session on Tuesday, up 55 cents, or 2%, to $23.93 on 1.7 million shares. The company announced on Monday it has begun dosing in a Phase 1 study of its new biologic therapy to treat auto-immune diseases and inflammatory disorders. The move broke the stock out of a week-long consolidation zone that followed its nearly 50% gap up on March 20. The move came on only average volume. Nonetheless, watch for a run at $26 short-term.
Western Digital Corp. WDC, +2.90% is on the move. Stock in the data-storage company has been up five days in a row since its March 21 close at $73.22. Investors appear to have been encouraged by Micron Technologys MU, +1.65% strong quarterly forecast late last week, and optimism about memory and storage chip demand. On Tuesday, WDC gained $1.99, or 2.5%, to $80.56, on nearly 4 million shares traded. The stock is right at a lateral resistance level, and a pop through there could get it to $86-$87 and then the channel top near $95.
See Harrys video chart analysis on these stocks.
Harry Boxer is founder of TheTechTrader.com, a live trading room featuring his stock picks, technical market analysis, and live chart presentations.
See more here:
Harry Boxer's five technology and biotechnology stocks to watch ... - MarketWatch
Posted: March 31, 2017 at 3:48 am
Prana Biotechnology Limited (ADR) (NASDAQ:PRAN)
Prana Biotechnology Limited (ADR) (NASDAQ:PRAN) shares have been up over 80% on large volumes. PRAN closed yesterday at $2.48, gapped up to open at $2.95, reached an inter-day high of $4.58, and are now trading around $3.60 for an inter-day gain of over 45%. The nano-cap Australian-based biotech firm has, prior to todays action, an average daily trading volume of just over 59,000 but, by 10:30 AM EST, PRAN shares had already traded over 7.1 million times. A review of news services reveals that no news has been reported by the company or an analyst that could account for todays price action.
Prana Biotechnology Limited (ADR) (NASDAQ:PRAN) is a clinical stage biotechnology firm that develops therapeutic medicines. Prana has developed PBT-2 for the treatment of Alzheimers disease. PBT-2 is currently in a Phase IIa clinical trial. Pranas PBT-2 is also being investigated for applications involving other therapeutic applications including age-related cataracts, Huntington disease, Creutzfeldt-Jakob disease, Motor Neuron disease, age-related macular degeneration, cancers, Parkinsons disease, and other neurodegenerative diseases.
When PRAN is adjusted for dilutive effects, the shares high came in early 2014 when PRAN was trading near $80/share. However, by the end of 2014, PRAN shares would end up down over 74%. Dilution, EPS losses, and weak sales figures have plagued the shares. Prana Biotechnology Limited (ADR) (NASDAQ:PRAN) have reported sales of $100,000 every year since 2012 except for 2014 when the company reported a figure of $300,000. EPS losses have been noteworthy. In 2012 the EPS loss for shares holders of PRAN was -$5.00, followed by annual EPS losses of-$6.31, -$8.55, -$3.21, and -$3.98 in 2016. There has also been consistent dilution for PRN shareholders. In 2012 the number of outstanding shares was 800,000 and that number grew annually and in 2016 the number was 1.48 million. Given Prana Biotechnology Limited (ADR) (NASDAQ:PRAN) market cap of only $23 million and its lack of sales, no analysts have reviewed the companys share ratings since 2014.
I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.
About the author: Marc has a degree in economics and a MSc. in Finance. Over his 20-year career, Marc has worked for global investment firms in Europe and the United States as an analyst, fund manager, and consultant.
Marc Anderson is a pseudonym. Marc has a degree in economics and a MSc. in Finance. Marc worked for global investment firms in Europe and the United States as an analyst, fund manager, and consultant. View all posts by Marcus Anderson
Visit link:
Prana Biotechnology Limited (ADR) (NASDAQ:PRAN) Gains are ... - StockNewsUnion
Posted: March 31, 2017 at 3:48 am
With excellent mechanical and chemical stability, the Kromasil EternityXT materials offer first-rate separation power and loadability for purification from low to high pH. Kromasil EternityXT C8 and C18 materials can operate up to pH 12, making it possible to run basic compounds under extreme conditions to improve purification productivity and reduce costs. These products support discovery, development and production departmental goals in the purification of a low molecular weight pharmaceuticals, peptides and biotechnology products.
The exceptional structure of Kromasil EternityXT C18 and C8 materials makes it possible to regenerate the material in-column, carrying out cleaning in place (CIP) even at 1 M NaOH, if so required. While this high concentration NaOH treatment is a standard in bio chromatography and until now only conceivable with polymer resins, Kromasil EternityXT materials open up the spectrum of purification options as its C8 and C18 materials resist up to 1 M NaOH.
Read the rest here:
Purification of Pharmaceutical and Biotechnology Products with Kromasil EternityXT Stationary Phase - Labmate Online
Posted: March 31, 2017 at 3:48 am
BRADENTON, Fla. By now, the time line for recovery from Tommy John surgery is familiar even to the casual baseball fan. It takes at least a year, usually more. It takes tedious, monotonous work on the part of the player.
Alternatives exist, but until now their use among established major leaguers has been limited if tried at all. This season could provide a referendum on two of them. One surgical procedure could cut the recovery time in half. Another treatment could help a player avoid surgery altogether.
I think it can definitely help the game, right-hander Seth Maness, who had a modified elbow ligament surgery in August, said by phone from spring training in Arizona. But the circumstances have to be right.
Maness had a surgery on his right elbow known as a primary repair or primary brace. The procedure reattaches the elbows ulnar collateral ligament to the bone with collagen-coated Arthrex tape. Los Angeles Angels starter Garrett Richards received a stem cell injection into his right elbow to heal his damaged UCL. So far, its working.
The last thing you want to do is have surgery, and if you do what your body does naturally, thats going to be stronger than any replacement surgery, Richards said, also by phone from spring training in Arizona. I just hope that this further gives guys a little bit of knowledge that you have options.
Neither procedure will replace Tommy John. Stem cells dont work in every case, and if the UCL is torn across the middle of the ligament, it needs to be replaced. The sample size for both is also small. But both provide options involving less recovery time for pitchers whose injuries fit a certain profile.
Maness, 28, spent four seasons pitching out of the St. Louis Cardinals bullpen and signed a minor league contract with the Kansas City Royals in February. Maness ligament had pulled away from the bone rather than tearing across the middle. Instead of needing a full Tommy John surgery, which requires grafting a tendon from the wrist or hamstring into the elbow to replace the UCL and at least a year of recovery, Maness was a candidate for a primary repair.
Really this primary brace technology had been used more widely in Europe, particularly for ligament injuries of the knee and the ankle, said Dr. George Paletta, St. Louis Cardinals head orthopedic surgeon who performed Maness surgery. So the concept or the idea was, OK, its working well there, is there a way to adapt it to the elbow?
Paletta had done roughly 60 primary repairs on amateur pitchers prior to operating on Maness and saw an average recovery time of 6 months. That background helped him establish three criteria he needed a young pitcher, an otherwise healthy ligament and, most importantly,the ligament needed to pull off the bone on one end rather than tear in the middle.
Weve had a lot of experience with ligaments healing directly to bone and we have a good understanding of that timetable, so we knew that by about 12 weeks after surgery, this repair should be pretty well healed and pretty solid at that point, Paletta said.
Cardinals reliever Mitch Harris also had the primary repair, as did a third pitcher with major league experience, according to the St. Louis Post-Dispatch, with whom Maness first discussed the procedure in January. Cardinals non-roster outfielder/pitcher Jordan Schafer had the procedure this month.
The UCL in Richards right elbow had a tear running along the ligament, not across it. He sought second opinions from noted orthopedic surgeons Dr. James Andrews and Dr. Neal ElAttrache.
Dr. Andrews pretty much told me, Hey Garrett, if you were my son, I would try the stem cell first, Richards said.
Doctors removed stem cells from his pelvis and injected them into his elbow, in hopes the cells would heal the UCL. Stem cells, extracted from bone marrow, are able to develop into multiple different tissues and can promote healing.
It just feels tight. Youre putting fluid into a place that pretty much doesnt have any room for any more fluid, Richards said of the injection. If you can imagine youre just overfilling a certain area with this nice special sauce.
Teams sometimes use platelet-rich plasma injections, where blood is spun in a centrifuge to isolate growth factors Takashi Saitos PRP injection in 2008 was believed to be the first for a major league pitcher, and Masahiro Tanaka also has pitched successfully with a partially torn UCL after PRP treatment but stem cells are less common. Bartolo Colon, soldiering into his 20th major league season at 43 years old, had a stem cell treatment in 2010. Boston Red Sox left-hander Drew Pomeranz had a stem cell injection in his elbow this winter to address lingering soreness.But Pomeranz went on the disabled list Thursday with left forearm flexor strain.
It doesnt always work. Richards teammate, lefty Andrew Heaney, needed Tommy John last summer after stem cells didnt do the trick.
Richards six-week exam showed significant growth. His three-month check showed even more. He reported no issues this spring, his high-90s mph fastball is back and he is on track to open the season in the rotation.
Everything feels great, Richards said. Basically I took the year off, let my arm heal and now Im back doing what I always do. I just feel refreshed.
Bill Brink: bbrink@post-gazette.com and Twitter @BrinkPG.
Read the original post:
How new-age medicine is helping Major League Baseball pitchers avoid injury - Pittsburgh Post-Gazette
Posted: March 31, 2017 at 3:48 am
March 30, 2017
Researchers have developed a new approach for growing and studying cells they hope one day will lead to curing lung diseases such as cystic fibrosis through "personalized medicine."
Researchers at the Center for Regenerative Medicine (CReM) at Boston University School of Medicine (BUSM) and Boston Medical Center (BMC) have discovered that one particular signaling pathway, Wnt, helps direct lung development. A signaling pathway is how developing cells get instruction on what types of cell to become, such as a liver cell, a skin cell, a brain cell, etc.
Using this finding, researchers implemented a new way to use stem cells made from any individual, including cells from patients with cystic fibrosis, and turn them into airway cells, which they then grew into three-dimensional spheres. These airway spheres now can be used to study cystic fibrosis disease activity using a specific test called a swelling assay.
"Because airway spheres from a patient with cystic fibrosis do not swell in our assay but airway spheres from a healthy person do, we can see whether adding a certain drug or combination of drugs causes them to swell more. Finding a drug that causes them to swell might imply that patient would benefit from that treatment," explained corresponding author Darrel Kotton, MD, director of the CReM and Seldin Professor of Medicine at BUSM.
"This study represents our progress towards making airway spheres from any patient with a lung disorder and learning about that patient's disease from those cells. We hope this leads to the ability to design, study and test new therapies for every patient on their own cells in the lab, leading to new treatments and breakthroughs in personalized medicine for individuals with a variety of lung diseases, including cystic fibrosis," explained lead author Katherine McCauley, a PhD student at BUSM.
The researchers believe this process can be used to study other lung diseases such as asthma and emphysema.
The findings are published in the journal Cell Stem Cell.
Explore further: Researchers engineer new thyroid cells
Researchers have discovered a new efficient way to generate thyroid cells, known as thyrocytes, using genetically modified embryonic stem cells.
The lungs contain a thin layer of fluid known as the airway surface liquid (ASL), which helps protect against pathogens. The appropriate ASL volume, pH, and ionic composition are required for optimal airway defense. Cystic ...
Researchers at the University of Toronto and the Hospital for Sick Children (SickKids) are paving the way towards individualized medicine for patients with cystic fibrosis.
Scientists at the University of Cambridge have successfully created 'mini-lungs' using stem cells derived from skin cells of patients with cystic fibrosis, and have shown that these can be used to test potential new drugs ...
It may be possible one day to treat several lung diseases by introducing proteins that direct lung stem cells to grow the specific cell types needed to repair the lung injuries involved in the conditions, according to new ...
Researchers from the European Bioinformatics Institute (EMBL-EBI), University of Cambridge, the Wellcome Trust Sanger Institute and the Cancer Research UK-Cambridge Institute (CRUK-CI) have shed light on a long-standing debate ...
(Medical Xpress)A team of researchers from several institutions in the U.K. and one in the U.S. has developed a faster and cheaper way to figure out which drugs on the market might be useful for treating other ailments. ...
Gaucher disease is a genetic disorder of lipid metabolism. Sphingosine, a compound as enigmatic as the sphinx, plays a key role in this metabolic disorder. Scientists from the Bonn research center caesar have identified some ...
Researchers have developed a new approach for growing and studying cells they hope one day will lead to curing lung diseases such as cystic fibrosis through "personalized medicine."
Activated by cold, the small amounts of brown fat scattered around your body can burn calories to warm you up. They also can help to lower insulin resistance and other conditions implicated in type 2 diabetes and obesity. ...
Doctors seeking a cure for an aggressive form of multiple sclerosis keep chasing a mirage: no matter how well a drug works in the lab, it never seems to help many patients in the clinic. But after closely examining stem cells ...
Please sign in to add a comment. Registration is free, and takes less than a minute. Read more
See the rest here:
New research finds novel method for generating airway cells from stem cells - Medical Xpress
Posted: March 31, 2017 at 3:48 am
March 30, 2017
Researchers at Case Western Reserve University School of Medicine have successfully grown stem cells from children with a devastating neurological disease to help explain how different genetic backgrounds can cause common symptoms. The work sheds light on how certain brain disorders develop, and provides a framework for developing and testing new therapeutics. Medications that appear promising when exposed to the new cells could be precisely tailored to individual patients based on their genetic background.
In the new study, published in The American Journal of Human Genetics, researchers used stem cells in their laboratory to simultaneously model different genetic scenarios that underlie neurologic disease. They identified individual and shared defects in the cells that could inform treatment efforts.
The researchers developed programmable stem cells, called induced pluripotent stem cells, from 12 children with various forms of Pelizaeus-Merzbacher Disease, or PMD. The rare but often fatal genetic disease can be caused by one of hundreds of mutations in a gene critical to the proper production of nerve cell insulation, or myelin. Some children with PMD have missing, partial, duplicate, or even triplicate copies of this gene, while others have only a small mutation. With so many potential causes, researchers have been in desperate need of a way to accurately and efficiently model genetic diseases like PMD in human cells.
By recapitulating multiple stages of the disease in their laboratory, the researchers established a broad platform for testing new therapeutics at the molecular and cellular level. They were also able to link defects in brain cell function to patient genetics.
"Stem cell technology allowed us to grow cells that make myelin in the laboratory directly from individual PMD patients. By studying a wide spectrum of patients, we found that there are distinct patient subgroups.
This suggests that individual PMD patients may require different clinical treatment approaches," said Paul Tesar, PhD, study lead, Dr. Donald and Ruth Weber Goodman Professor of Innovative Therapeutics, and Associate Professor of Genetics and Genome Sciences at Case Western Reserve University School of Medicine.
The researchers watched in real-time as the patients' stem cells matured in the laboratory. "We leveraged the ability to access patient-specific brain cells to understand why these cells are dysfunctional. We found that a subset of patients exhibited an overt dysfunction in certain cellular stress pathways," said Zachary Nevin, first author of the study and MD/PhD student at Case Western Reserve University School of Medicine. "We used the cells to create a screening platform that can test medications for the ability to restore cell function and myelin. Encouragingly, we identified molecules that could reverse some of the deficits." The promising finding provides proof-of-concept that medications that mend a patient's cells in the laboratory could be advanced to clinical testing in the future.
The stem cell platform could also help other researchers study and classify genetic diseases with varied causes, particularly other neurologic disorders. Said Tesar, "Neurological conditions present a unique challenge, since the disease-causing cells are locked away in patients' brains and inaccessible to study. With these new patient-derived stem cells, we can now model disease symptoms in the laboratory and begin to understand ways to reverse them."
Explore further: Researchers turn urine into research tools
Each face is unique, even though the genes controlling facial shape are almost identical in every individual. Filippo Rijli and his team at the Friedrich Miescher Institute for Biomedical Research (FMI) have discovered an ...
Researchers at Case Western Reserve University School of Medicine have successfully grown stem cells from children with a devastating neurological disease to help explain how different genetic backgrounds can cause common ...
By inserting an amyotrophic lateral sclerosis (ALS)-linked human gene called TDP-43 into fruit flies, researchers at Stony Brook University and Cold Spring Harbor Laboratory discovered a potential role for 'transposons' in ...
A genetic trawl through the DNA of almost 100,000 people, including 17,000 patients with the most common type of ovarian cancer, has identified 12 new genetic variants that increase risk of developing the disease and confirmed ...
In a research effort that merged genetics, physics and information theory, a team at the schools of medicine and engineering at The Johns Hopkins University has added significantly to evidence that large regions of the human ...
An international consortium of researchers led by Dr. Melissa Bondy, professor of medicine, associate director for population sciences at the Dan L Duncan Comprehensive Cancer Center and McNair Scholar at Baylor College of ...
Please sign in to add a comment. Registration is free, and takes less than a minute. Read more
Here is the original post:
Stem cells help explain varied genetics behind rare neurologic ... - Medical Xpress
Posted: March 31, 2017 at 3:48 am
Osiris Therapeutics Launches Prestige Lyotechnology, a Novel Method for Ambient Storage of Living Cells and Tissues
COLUMBIA, Md., March 30, 2017 -- Osiris Therapeutics, Inc. (Pink Sheets:OSIR), a leading regenerative medicine company focused on developing and marketing products for wound care, orthopedics, and sports medicine, announced today that it has developed cutting edge technology enabling the preservation of living cells and tissues at ambient temperatures.
Historically, cryopreservation was the only available method that allowed for long-term preservation of living cells and tissues. However, cryopreservation requires ultra-low-temperature freezers and dry ice or liquid nitrogen for storage, which limits the widespread use of cellular therapies. To address this limitation, Osiris has developed Prestige Lyotechnology. Unlike all other known lyophilization methods, Prestige Lyotechnology enables the preservation of living cells within tissues while stored at ambient temperatures. Moreover, the manufacturing of lyopreserved living tissues with Prestige Lyotechnology is scalable and can be applied to many different cell and tissue types. Placental products will be the focus of the Companys first application of Prestige Lyotechnology.
This novel technology developed by Osiris will benefit the entire field of cellular therapies. It is expected to accelerate development, commercialization and widespread use of living cell and tissue therapies, said Alla Danilkovitch, Chief Scientific Officer at Osiris. Through more than two decades of basic and clinical research, Osiris has not only defined the science and potential of cellular regenerative therapies, but has also created a body of work, advancing the medical communitys understanding of cellular technology. With the introduction of Prestige Lyotechnology, Osiris is bringing these innovative cellular therapies to more patients to address a wide range of unmet medical needs.
The Osiriss Prestige Lyotechnology is featured in tomorrows online publication of Osiriss profile in the scientific journal Nature (www.nature.com), entitled Innovation on the shelf: solving the puzzle of live-cell preservation. The print version of this article will appear in the special annual MedTech Dealmakers issue of Nature Medicine, Nature Biotechnology and Nature Reviews Drug Discovery in May. Nature is the worlds most highly cited international, interdisciplinary science journal.
About Osiris Therapeutics Osiris Therapeutics, Inc., based in Columbia, Maryland, is a world leader in researching, developing, and marketing regenerative medicine products that improve health and lives of patients and lower overall healthcare costs. Having developed the world's first approved stem cell drug, the Company continues to advance its research and development in biotechnology by focusing on innovation in regenerative medicine including bioengineering, stem cell research and viable tissue based products. Osiris has achieved commercial success with products in wound care, orthopedics, and sports medicine, including Grafix, Stravix, BIO4 , and Cartiform. Osiris, Grafix, Stravix and Cartiform are trademarks of Osiris Therapeutics, Inc., and BIO4 is a trademark of Howmedica Osteonics Corp. More information can be found on the Companys website, http://www.Osiris.com. (OSIR-G)
Forward-Looking Statements This press release contains forward-looking statements. Forward-looking statements include statements about our expectations, beliefs, plans, objectives, intentions, assumptions and other statements that are not historical facts. Words or phrases such as "anticipate," "believe," "continue," "ongoing," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project" or similar words or phrases, or the negatives of those words or phrases, may identify forward-looking statements, but the absence of these words does not necessarily mean that a statement is not forward-looking. Examples of forward-looking statements may include, without limitation, statements regarding the potential uses of Prestige Lyotechnology and the publication of Osiriss profile in Nature (www.nature.com). Forward-looking statements are subject to known and unknown risks and uncertainties and are based on potentially inaccurate assumptions that could cause actual results to differ materially from those expected or implied by the forward-looking statements. Accordingly, you should not unduly rely on these forward-looking statements. We undertake no obligation to publicly revise any forward-looking statement to reflect circumstances or events after the date of this press release or to reflect the occurrence of unanticipated events.
Human Life Could Be Extended Indefinitely, Study Suggests
Goosebumps, tears and tenderness: what it means to be moved
Are over-the-counter painkillers a waste of money?
Does an anomaly in the Earth's magnetic field portend a coming pole reversal?
Immunotherapy: Training the body to fight cancer
Do vegetarians live longer? Probably, but not because they're vegetarian
Could a contraceptive app be as good as the pill?
Some scientific explanations for alien abduction that aren't so out of this world
Society actually does want policies that benefit future generations
Six cosmic catastrophes that could wipe out life on Earth
Big Pharma Starts Using Cannabis For Making Drugs In Earnest
Do you need to worry if your baby has a flat head?
Continue reading here:
Osiris Therapeutics Launches Prestige Lyotechnology a Novel Method for Ambient Storage of Living Cells and Tissues - EconoTimes
